How can cancer research be illuminated by brain research (and vice versa)?
Alzheimer disease
brain
cancer
next-generation sequencing
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 12 2023
15 12 2023
Historique:
revised:
27
07
2023
received:
10
06
2023
accepted:
28
07
2023
medline:
23
10
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
Cancer and brain research have historically followed concrete pathways and converged mostly to studying brain cancer. Nowadays, the fields of neuro-oncology and neuroendocrine regulation of tumorigenesis are both emerging fields of intense research and promising applications. An increasing body of evidence suggests that somatic mutations in cancer-related genes are prevalent in several noncancerous brain disorders. These findings highlighting that certain aspects of cancer development/progression and pathologies of the nervous system share molecular alterations, could assist in elucidating the unique hallmarks of cancer and in cancer drugs repurposing for brain disorders. In so doing, identifying the commonalities in these conditions could be crucial not only for better understanding the basis of these pathologies but also for considering the previously underappreciated and/or neglected possibility of using drugs known to be effective in one type of pathology for the other type.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1967-1970Informations de copyright
© 2023 UICC.
Références
Frank SA. Evolution in health and medicine Sackler colloquium: somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc Natl Acad Sci U S A. 2010;107(Suppl 1):1725-1730.
Bruschi M, Grill J, Guerrini-Rousseau L. Pediatric brain tumors as a developmental disease. Curr Opin Oncol. 2021;33:608-614.
Krishna S, Choudhury A, Keough MB, et al. Glioblastoma remodelling of human neural circuits decreases survival. Nature. 2023;617:599-607.
Mass E, Jacome-Galarza CE, Blank T, et al. A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017;549:389-393.
Li B, Li K, Tian D, et al. De novo mutation of cancer-related genes associates with particular neurodevelopmental disorders. J Mol Med. 2020;98:1701-1712.
Lodato MA, Woodworth MB, Lee S, et al. Somatic mutation in single human neurons tracks developmental and transcriptional history. Science. 2015;350:94-98.
Khoshkhoo S, Wang Y, Chahine Y, et al. Contribution of somatic Ras/Raf/mitogen-activated protein kinase variants in the hippocampus in drug-resistant mesial temporal lobe epilepsy. JAMA Neurol. 2023;80:578-587.
Jamuar SS, Lam A-TN, Kircher M, et al. Somatic mutations in cerebral cortical malformations. N Engl J Med. 2014;371:733-743.
Gripp KW, Lin AE. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. Genet Med. 2012;14:285-292.
van der Willik KD, Schagen SB, Ikram MA. Cancer and dementia: two sides of the same coin? Eur J Clin Invest. 2018;48:e13019.
Hunt T. You never know: Cdk inhibitors as anti-cancer drugs. Cell Cycle. 2008;7:3789-3790.
Joseph C, Mangani AS, Gupta V, et al. Cell cycle deficits in neurodegenerative disorders: uncovering molecular mechanisms to drive innovative therapeutic development. Aging Dis. 2020;11:946-966.
Alfonso SI, Callender JA, Hooli B, et al. Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease. Sci Signal. 2016;9:ra47.
Antal CE, Hudson AM, Kang E, et al. Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell. 2015;160:489-502.
Lee M-H, Siddoway B, Kaeser GE, et al. Somatic APP gene recombination in Alzheimer's disease and normal neurons. Nature. 2018;563:639-645.
Park JS, Lee J, Jung ES, et al. Brain somatic mutations observed in Alzheimer's disease associated with aging and dysregulation of tau phosphorylation. Nat Commun. 2019;10:3090.
Gómez-González B, Aguilera A. Transcription-mediated replication hindrance: a major driver of genome instability. Genes Dev. 2019;33:1008-1026.
Duran D, Zeng X, Jin SC, et al. Mutations in chromatin modifier and ephrin signaling genes in vein of Galen malformation. Neuron. 2019;101:429-443.
Xiao Z, Carrasco R, Kinneer K, et al. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: implications for EphB4 as a cancer target. Cancer Biol Ther. 2012;13:630-637.
Ren AA, Snellings DA, Su YS, et al. PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. 2021;594:271-276.
Peyre M, Miyagishima D, Bielle F, et al. Somatic PIK3CA mutations in sporadic cerebral cavernous malformations. N Engl J Med. 2021;385:996-1004.
Weng J, Yang Y, Song D, et al. Somatic MAP3K3 mutation defines a subclass of cerebral cavernous malformation. Am J Hum Genet. 2021;108:942-950.
Zhou Z, Tang AT, Wong W-Y, et al. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature. 2016;532:122-126.
Matafora V, Farris F, Restuccia U, et al. Amyloid aggregates accumulate in melanoma metastasis modulating YAP activity. EMBO Rep. 2020;21:e50446.
Venkatesh HS, Johung TB, Caretti V, et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell. 2015;161:803-816.
Frémond ML, Hully M, Fournier B, et al. JAK inhibition in Aicardi-Goutières syndrome: a monocentric multidisciplinary real-world approach study. J Clin Immunol. 2023;43:1436-1447.
Baghdassarian H, Blackstone SA, Clay OS, et al. Variant STAT4 and response to Ruxolitinib in an autoinflammatory syndrome. N Engl J Med. 2023;388:2241-2252.
Geoerger B, Schiff M, Penard-Lacronique V, et al. Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation. Nat Med. 2023;29:1358-1363.